EGFR and non-small cell lung carcinoma: In the single‐arm phase II LUMINOSITY trial (NCT03539536), ABBV‐399 demonstrated promising results in the treatment of MET protein overexpressing, EGFR WT, advanced/metastatic non‐squamous NSCLC.